Bulluck Heerajnarain, Foin Nicolas, Tan Jack W, Low Adrian F, Sezer Murat, Hausenloy Derek J
From the Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, United Kingdom (H.B., D.J.H.); The National Institute of Health Research, University College London Hospitals, Biomedical Research Centre, United Kingdom (H.B., D.J.H.); Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore (H.B., N.F., D.J.H.); National Heart Research Institute Singapore, National Heart Centre Singapore (H.B., N.F., J.W.T., D.J.H.); National University Heart Centre, Singapore (A.F.L.); Department of Cardiology, Istanbul University, Istanbul Faculty of Medicine, Çapa, Turkey (M.S.); Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (D.J.H.); and Yong Loo Lin School of Medicine, National University Singapore (D.J.H.).
Circ Cardiovasc Interv. 2017 Mar;10(3). doi: 10.1161/CIRCINTERVENTIONS.116.004373.
For patients presenting with an acute ST-segment-elevation myocardial infarction, the most effective therapy for reducing myocardial infarct size and preserving left ventricular systolic function is primary percutaneous coronary intervention (PPCI). However, mortality and morbidity remain significant. This is partly attributed to the development of microvascular obstruction, which occurs in around 50% of ST-segment-elevation myocardial infarction patients post-PPCI, and it is associated with adverse left ventricular remodeling and worse clinical outcomes. Although microvascular obstruction can be detected by cardiac imaging techniques several hours post-PPCI, it may be too late to intervene at that time. Therefore, being able to predict the development of microvascular obstruction at the time of PPCI may identify high-risk patients who might benefit from further adjuvant intracoronary therapies, such as thrombolysis, vasodilators, glycoprotein IIb/IIIa inhibitors, and anti-inflammatory agents that may reduce microvascular obstruction. Recent studies have shown that invasive coronary physiology measurements performed during PPCI can be used to assess the coronary microcirculation. In this article, we provide an overview of the various invasive methods currently available to assess the coronary microcirculation in the setting of ST-segment-elevation myocardial infarction, and how they could potentially be used in the future for tailoring therapies to those most at risk.
对于急性ST段抬高型心肌梗死患者,降低心肌梗死面积并保留左心室收缩功能的最有效治疗方法是直接经皮冠状动脉介入治疗(PPCI)。然而,死亡率和发病率仍然很高。这部分归因于微血管阻塞的发生,约50%的ST段抬高型心肌梗死患者在PPCI后会出现微血管阻塞,它与不良的左心室重构及更差的临床结局相关。虽然在PPCI数小时后可通过心脏成像技术检测到微血管阻塞,但此时进行干预可能为时已晚。因此,在PPCI时能够预测微血管阻塞的发生,可能会识别出可能从进一步的辅助冠状动脉内治疗中获益的高危患者,这些治疗包括溶栓、血管扩张剂、糖蛋白IIb/IIIa抑制剂以及可能减少微血管阻塞的抗炎药物。最近的研究表明,在PPCI期间进行的有创冠状动脉生理学测量可用于评估冠状动脉微循环。在本文中,我们概述了目前可用于评估ST段抬高型心肌梗死背景下冠状动脉微循环的各种有创方法,以及它们未来如何有可能用于为高危患者量身定制治疗方案。